<DOC>
	<DOCNO>NCT01618370</DOCNO>
	<brief_summary>This study prospective , interventional , open-label , multi-center early access program use Ra-223 Cl2 HRPC/CRPC ( Hormone refractory prostate cancer / Castrate resistant prostate cancer ) patient diagnose bone metastasis collect additional short long term safety data product .</brief_summary>
	<brief_title>Radium ( 223 ) Dichloride ( Alpharadin ) Castration-Resistant ( Hormone-Refractory ) Prostate Cancer Patients With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Age ≥18 year age Histologically cytologically confirm prostate cancer Patients diagnose progressive bone predominant metastatic CRPC/HRPC ( Hormone refractory prostate cancer / Castrate resistant prostate cancer ) least 2 skeletal metastasis image lung , liver , and/or brain metastasis ( lymph node metastasis allow ) Progressive disease define either : The appearance new bone lesion . If progression base new lesion ( ) image without increase prostate specific antigen ( PSA ) , PSA value 3 assessment within last 6 month must provide ; OR In absence new bone lesion 2 subsequent increase serum PSA previous reference value , 6 month screen , measure least 1 week apart last PSA ≥ 5 ng/mL . ( The reference value time point 1 , define last PSA measure increase document , subsequent value obtain minimum 1 week apart . If PSA time point 3 great PSA time point 2 , eligibility meet . If PSA time point 3 great PSA time point 2 PSA value time point 4 and/or time point 5 great PSA time point 2 , patient eligible assume criterion meet ) Life expectancy ≥ 6 month Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 2 Adequate hematological , liver , renal function Absolute neutrophil count ( ANC ) ≥ 1.5 x10^9/L Platelet count ≥ 100 x10^9/L Hemoglobin ≥ 10.0 g/dL ( 100 g/L ; 6.2 mmol/L ) Total bilirubin level ≤ 1.5 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN Creatinine ≤ 1.5 x ULN Albumin &gt; 25 g/L Treatment investigational drug within previous 4 week , plan treatment period followup Eligible first course docetaxel , i.e. , patient fit enough , willing , locate treatment docetaxel available Treatment cytotoxic chemotherapy within previous 4 week , failure recover AEs ( adverse event ) due cytotoxic chemotherapy administer 4 week previous ( however , ongoing neuropathy permit ) Prior hemibody external radiotherapy exclude . Patients receive type prior external radiotherapy allow provide bone marrow function assess meet protocol requirement hemoglobin , absolute neutrophil count platelet Received systemic therapy radionuclides ( e.g. , strontium89 , samarium153 , rhenium186 , rhenium188 , radium223 dichloride ) treatment bony metastases Other malignancy treat within last 3 year ( except non melanoma skin cancer lowgrade superficial bladder cancer ) Visceral metastasis assess abdominal pelvic compute tomography ( CT ) ( image modality base institutional standard care ) Presence brain metastasis Lymphadenopathy exceed 6 cm shortaxis diameter Any size pelvic lymphadenopathy think contributor concurrent hydronephrosis Imminent history spinal cord compression base clinical finding and/or magnetic resonance imaging ( MRI ) . Patients history spinal cord compression completely recover . Any serious illness medical condition , limited : Any infection ≥ National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) version 4.03 Grade 2 Cardiac failure New York Heart Association ( NYHA ) III IV Crohn 's disease ulcerative colitis Bone marrow dysplasia Fecal incontinence</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radium 223</keyword>
	<keyword>Alpharadin</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Bone metastasis</keyword>
	<keyword>Castrate resistant prostate cancer</keyword>
	<keyword>Hormone refractory prostate cancer</keyword>
</DOC>